







## Active substances set

**Search phrase:** Chronic myeloid leukemia

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

### Chronic myeloid leukemia

<b>Bosutinib</b>	<p>Bosutinib is indicated for the treatment of adult patients with: - newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML), - CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.</p>	 <b>REIMBURSEMENT WITH RESTRICTIONS</b>   <b>ESMO</b>
<b>Ponatinib</b>	<p>Ponatinib is indicated in adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.</p>	 <b>FULL REIMBURSEMENT</b>   <b>ESMO</b>
<b>Asciminib</b>	<p>Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors.</p>	 <b>FULL REIMBURSEMENT</b>   <b>ESMO</b>